By Fineline Cube 
US-Irish firm Medtronic (NYSE: MDT) released financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Medtronic’s FY25Q4 revenue reached USD 8.927 billion, up 3.9% year-on-year (YOY) based on reported data. Operating profit increased by 36% to USD 1.4 billion. For the full fiscal year, Medtronic reported annual revenue of USD 33.537 billion, up 3.6% YOY, with operating profit growing by 16% to USD 6 billion.
Business Segment Performance
By business segment, in Q4, Medtronic’s cardiovascular business generated USD 3.336 billion (+6.6%) in sales, the neuroscience product portfolio took home USD 2.62 billion (+2.9%), the medical surgical portfolio brought in USD 2.212 billion (+0.6%), and the diabetes business pulled down USD 728 million (+10.4%) in sales. For FY25, the revenues of the cardiovascular business, neuroscience product portfolio, medical surgical portfolio, and diabetes business stood at USD 12.481 billion (+5.5%), USD 9.846 billion (+4.7%), USD 8.407 billion (-0.1%), and USD 2.755 billion (+10.7%) respectively.
Cardiac Ablation Business
Driven by pulsed field ablation (PFA) products, the cardiac ablation solution business saw a revenue growth of nearly 30% in Q4 and a full-year revenue of USD 1 billion in FY25. This segment’s strong performance highlights Medtronic’s continued innovation and market leadership in cardiac solutions.
Diabetes Business Spinoff
On the same day, Medtronic announced its intention to spin off its diabetes business into a new independent listed company. This strategic move aims to focus Medtronic’s core operations while allowing the diabetes business to operate with greater agility and independence.-Fineline Info & Tech